Waycross Partners Increases AbbVie Stock Holdings

Institutional investor adds over 5,000 shares to biotech giant's portfolio

Mar. 29, 2026 at 11:24am

Got story updates? Submit your updates here. ›

Waycross Partners LLC, an institutional investor, increased its stake in AbbVie Inc. (NYSE:ABBV) by 2.9% in the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 182,476 shares of the biopharmaceutical company's stock, valued at $41,694,000.

Why it matters

AbbVie is a major player in the pharmaceutical industry, with a diverse portfolio of specialty medicines across immunology, oncology, neuroscience, and other therapeutic areas. Institutional investors closely monitor changes in ownership of large-cap biotech stocks like AbbVie, as it can signal broader market sentiment and future growth potential.

The details

Waycross Partners added 5,063 shares to its AbbVie position during the fourth quarter, bringing its total stake to 182,476 shares. The firm's investment in AbbVie now accounts for 3.4% of its overall portfolio. AbbVie's stock price has fluctuated in recent months, with the company facing both growth opportunities and competitive pressures in its key drug markets.

  • Waycross Partners increased its AbbVie stake in the fourth quarter of 2025.
  • The 13F filing disclosing the increased position was published on March 29, 2026.

The players

Waycross Partners LLC

An institutional investor that manages a diversified portfolio of stocks, including a significant position in pharmaceutical giant AbbVie.

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Waycross Partners in AbbVie reflects the continued interest and confidence that institutional investors have in the biotech company's long-term growth potential, despite recent market volatility.